title: Clinical and radiological outcome of total hip replacement five years after pamidronate therapy. A trial extension.
abstract: Bisphosphonates reduce peri-prosthetic bone loss in the short term after total hip replacement but the mid- and longer term effects are not known. The aims of this randomised trial were to examine the effect of a single dose of 90 mg of pamidronate on the clinical and radiological outcome and peri-prosthetic bone mineral density in 50 patients (56 hips) over a five-year period, following total hip replacement. At five years, 37 patients (42 hips) returned for assessment. The Harris hip scores were similar in the pamidronate and placebo groups throughout the study. Also at five years, four patients, two from each group had osteolytic lesions on plain radiography. These were located around the acetabular component in three patients and in the femoral calcar in one. The femoral and acetabular peri-prosthetic bone mineral density in the pamidronate group and the control group was similar at five years. Pamidronate given as a single post-operative dose does not appear to influence the clinical outcome or prevent the development of osteolytic lesions at five years after total hip replacement.
authors.affiliation: Department of Orthopaedics, University of Sheffield, Northern General Hosital, UK.
authors.forename: N
authors.initials: N
authors.lastname: Shetty
authors.forename: A J
authors.initials: AJ
authors.lastname: Hamer
authors.forename: I
authors.initials: I
authors.lastname: Stockley
authors.forename: R
authors.initials: R
authors.lastname: Eastell
authors.forename: J M
authors.initials: JM
authors.lastname: Willkinson
mesh_terms: D015502:Absorptiometry, Photon / Q000379:methods; D000077:Acetabulum / Q000503:physiopathology; D000328:Adult; D000368:Aged; D019644:Arthroplasty, Replacement, Hip; D015519:Bone Density / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005269:Femur / Q000503:physiopathology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D015207:Osteoarthritis, Hip / Q000150:complications / Q000000981:diagnostic imaging / Q000601:surgery*; D010024:Osteoporosis / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000517:prevention & control*; D010147:Pain Measurement; D000077268:Pamidronate; D011183:Postoperative Complications; D016059:Range of Motion, Articular / Q000502:physiology; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077268:Pamidronate